Introduction: Synovetin OA (Exubrion Therapeutics), a novel preparation of the radionuclide tin-117
m embedded in a homogeneous colloid, has been developed for intra-articular (IA) administration
(radiosynoviorthesis) of the elbow to treat synovial inflammation associated with
osteoarthritis (OA) in dogs. Three clinical trials were conducted to assess efficacy
in dogs with radiographic elbow OA of the elbow.
Materials and Methods: Dogs with grade 1 or 2 elbow OA were assigned to Trial 1, dogs with grade 3 elbow
OA were assigned to Trial 2, and Trial 3 dogs obtained from the Trial 1 posttreatment
population were assigned to a 1-year reinjection study. Efficacy was based on a composite
of the Canine Brief Pain Inventory (CBPI) completed by the dog owner, clinician assessments
of lameness, and force-plate gait analyses.
Results: The per-protocol populations had treatment success rates of 88.2, 71.4, and 66.7%
respectively in Trial 1 dogs (n = 34), Trial 2 dogs (n = 14), and Trial 3 dogs (n = 9) dogs. Force-plate gait analyses conducted for 22 dogs showed a treatment success
rate of 81.8% (p = 0.0022).
Discussion/Conclusion: Trial results indicated that Synovetin OA provided reduction in pain and lameness
for up to 1 year in dogs with clinical OA.
Acknowledgment: Drs. Jimmy Lattimer, Lorie Gaschen, Karanvir Aulakh, Micelle Fabiani, Brian Beale
and Caleb Hudson.
